2020-003640-88: A long-term safety surveillance study in participants previously treated with 177Lu-IPN01072 |
|
|
| Not yet recruiting | 1/2 | 38 | Europe | 177Lu-satoreotide tetraxetan, 177Lu-SSO110, 177Lu-IPN01072,177Lu-OPS201, Solution for injection | Ariceum Therapeutics GmbH, Ariceum Therapeutics GmbH | Neuroendocrine tumors (NETs), Neuroendocrine tumors (NETs), neoplasms that arise from cells of the endocrine (hormonal) and nervous systems., Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Investigative Techniques [E05] | | | | |
ACTRN12623000185662: Satoreotide Theranostic Pilot study in Extensive Stage in Small Cell Lung Cancer (ES-SCLC)
|
|
|
| Recruiting | 1 | 70 | | | Ariceum Therapeutics Australia Pty Ltd, Ariceum Therapeutics Australia Pty Ltd | Extensive Stage Small Cell Lung Cancer | | | | |
PROMENADE, NCT04997317: Treatment of Recurrent or Progressive Meningiomas With the Radiolabelled Somatostatin Antagonist 177Lu-satoreotide |
|
|
| Recruiting | 1 | 18 | Europe | 177Lu-DOTA-JR11 (Phase 0); Cycle 1 and Cycle 2 (cross-over), 177Lu-DOTATOC (Phase 0); Cycle 1 and Cycle 2 (cross-over), Cycle 3 and 4, 177Lu-DOTA-JR11 (Phase I/II) | University Hospital, Basel, Switzerland, Swiss Cancer League | Meningioma | 12/25 | 12/25 | | |